| Literature DB >> 27152687 |
Robert R Edwards1, Robert H Dworkin2, Dennis C Turk3, Martin S Angst4, Raymond Dionne5, Roy Freeman1, Per Hansson6, Simon Haroutounian7, Lars Arendt-Nielsen8, Nadine Attal9, Ralf Baron10, Joanna Brell11, Shay Bujanover12, Laurie B Burke13,14, Daniel Carr15, Amy S Chappell16, Penney Cowan17, Mila Etropolski18, Roger B Fillingim19, Jennifer S Gewandter2, Nathaniel P Katz15,20, Ernest A Kopecky21, John D Markman2, George Nomikos22, Linda Porter23, Bob A Rappaport24, Andrew S C Rice25, Joseph M Scavone26, Joachim Scholz27, Lee S Simon28, Shannon M Smith2, Jeffrey Tobias29, Tina Tockarshewsky30, Christine Veasley31, Mark Versavel32, Ajay D Wasan33, Warren Wen34, David Yarnitsky35.
Abstract
There is tremendous interpatient variability in the response to analgesic therapy (even for efficacious treatments), which can be the source of great frustration in clinical practice. This has led to calls for "precision medicine" or personalized pain therapeutics (ie, empirically based algorithms that determine the optimal treatments, or treatment combinations, for individual patients) that would presumably improve both the clinical care of patients with pain and the success rates for putative analgesic drugs in phase 2 and 3 clinical trials. However, before implementing this approach, the characteristics of individual patients or subgroups of patients that increase or decrease the response to a specific treatment need to be identified. The challenge is to identify the measurable phenotypic characteristics of patients that are most predictive of individual variation in analgesic treatment outcomes, and the measurement tools that are best suited to evaluate these characteristics. In this article, we present evidence on the most promising of these phenotypic characteristics for use in future research, including psychosocial factors, symptom characteristics, sleep patterns, responses to noxious stimulation, endogenous pain-modulatory processes, and response to pharmacologic challenge. We provide evidence-based recommendations for core phenotyping domains and recommend measures of each domain.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27152687 PMCID: PMC5965275 DOI: 10.1097/j.pain.0000000000000602
Source DB: PubMed Journal: Pain ISSN: 0304-3959 Impact factor: 7.926